Literature DB >> 15813844

Primary and secondary thrombocytosis in childhood.

Christof Dame1, Anton Heinz Sutor.   

Abstract

This review summarizes current data on the pathomechanisms and clinical aspects of primary and secondary thrombocytosis in childhood. Primary thrombocytosis is extremely rare in childhood, mostly diagnosed at the beginning of the second decade of life. As in adults, the criteria of the Polycythemia Vera Group are appropriate to diagnose primary thrombocytosis. The pathomechansims of non-familial forms are complex and include spontaneous formation of megakaryopoietic progenitors and increased sensitivity to thrombopoietin (Tpo). Familial forms can be caused by mutations in Tpo or Tpo receptor (c-mpl) genes. These mutations result in overexpression of Tpo, sustained intracellular signalling or disturbed regulation of circulating Tpo. Treatment of primary thrombocytosis is not recommended if platelet counts are <1500/nl and bleeding or thrombosis did not occur in patient's history. In severe cases, decision on treatment should weigh potential risks of treatment options (hydroxyurea, anagrelide) against expected benefits for preventing thrombosis or haemorrhage. Secondary thrombocytosis is frequent in children, in particular in the first decade of life. Hepatic Tpo production is stimulated in acute response reaction to a variety of disorders. Thrombosis prophylaxis is not required, even at platelet counts >1000/nl, except for cases with additional prothrombotic risk factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15813844     DOI: 10.1111/j.1365-2141.2004.05329.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  29 in total

1.  Clinicohematological study of thrombocytosis.

Authors:  Dinesh Yadav; Jagdish Chandra; Sunita Sharma; Varinder Singh
Journal:  Indian J Pediatr       Date:  2010-06-08       Impact factor: 1.967

2.  A 90-day subchronic feeding study of genetically modified rice expressing Cry1Ab protein in Sprague-Dawley rats.

Authors:  Huan Song; Xiaoyun He; Shiying Zou; Teng Zhang; Yunbo Luo; Kunlun Huang; Zhen Zhu; Wentao Xu
Journal:  Transgenic Res       Date:  2014-11-01       Impact factor: 2.788

3.  Comments on "essential thrombocytosis and antiphospholipid antibody syndrome causing chronic Budd-Chiari syndrome".

Authors:  Thein H Oo
Journal:  Indian J Pediatr       Date:  2011-12-20       Impact factor: 1.967

4.  Essential thrombocytosis and antiphospholipid antibody syndrome causing chronic Budd-Chiari syndrome.

Authors:  Dinesh Yadav; Jagdish Chandra; Sunita Sharma; Varinder Singh
Journal:  Indian J Pediatr       Date:  2011-08-10       Impact factor: 1.967

Review 5.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 6.  Special issues in myeloproliferative neoplasms.

Authors:  Tiziano Barbui; Guido Finazzi
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

Review 7.  Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease.

Authors:  Bryce A Kerlin; Rose Ayoob; William E Smoyer
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-16       Impact factor: 8.237

8.  Lamotrigine in breast milk and nursing infants: determination of exposure.

Authors:  D Jeffrey Newport; Page B Pennell; Martha R Calamaras; James C Ritchie; Melanee Newman; Bettina Knight; Adele C Viguera; Joyce Liporace; Zachary N Stowe
Journal:  Pediatrics       Date:  2008-06-30       Impact factor: 7.124

9.  Extreme thrombocytosis in admissions to paediatric intensive care: no requirement for treatment.

Authors:  Alison Denton; Peter Davis
Journal:  Arch Dis Child       Date:  2007-06       Impact factor: 3.791

Review 10.  Platelet abnormalities in nephrotic syndrome.

Authors:  Benedicte Eneman; Elena Levtchenko; Bert van den Heuvel; Chris Van Geet; Kathleen Freson
Journal:  Pediatr Nephrol       Date:  2015-08-13       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.